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A series of ferrocenyl ester complexes, varying the lipophilic character of the pendant groups, was prepared and characterized
by spectroscopic and analytical methods. The syntheses of Fe(C5H4CO2CH3)2, Fe(CpCOOCH3) (CpCOO CH2CH3), and
Fe(CpCOOCH2CH3)2 arereported.Thesolid-statestructureofFe(C5H4CO2CH3)2 hasbeendeterminedbyX-raycrystallography.
Fe(C5H4CO2CH3)2 has the cyclopentadienyl rings virtually in an eclipsed conformation with the pendant groups not
completely opposite to each other. Cyclic voltammetry characterization showed that the functionalized ferrocenes oxidize
at potentials, Epa, higher than ferrocene as a result of the electro withdrawing eﬀect of the pendant groups on the
cyclopentadienyl ligand. The cytotoxicities of Fe(C5H4CO2CH2CH2OH)2,F e ( C 5H4CO2CH2CH=CH2)2,F e ( C 5H4CO2CH3)2,
Fe(CpCOOCH3)(CpCOOCH2CH3), and Fe(CpCOOCH2CH3)2 in colon cancer HT-29 and breast cancer MCF-7 cell lines were
measured by the MTT biological viability assay and compared to ferrocene and ferrocenium. Fe(C5H4CO2CH2CH=CH2)2 showed
the best IC50 values, 180(10) μM for HT-29 and 190(30) μM for MCF-7 cell lines, with cytotoxicities similar to ferrocenium.
The cytotoxic data suggest that as we increase the lipophilic character of the functionalized ferrocene, the cytotoxicity improves
approaching to the cytotoxic activity of ferrocenium.
Copyright © 2009 Li Ming Gao et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Modern organometallic chemistry has been greatly inﬂu-
enced by the accidental discovery of bis(cyclopentadi-
enyl)iron(II) (ferrocene) in 1951 [1, 2]. In fact, ferrocene
(Cp2Fe) has been the most extensively studied organometal-
lic species. Its applications in catalysis, organic synthesis,
and industrial processes are numerous [3–6]. The thermal
stability, inert character in concentrated acid and base
solutions as well as the redox properties of ferrocene makes
this species a versatile compound in many research areas.
Until1979,thebiologicalpropertiesofmetalloceneswere
unexplored. The report of titanocene dichloride (Cp2TiCl2)
as the ﬁrst metallocene to possess antitumor activity opened
a new area of research, bioorganometallics, which has been
developing rapidly in the last twenty eight years [7, 8].
In 1984, K¨ opf-Maier et al. reported the anticancer
activity of ferrocenium complex in Ehrlich ascites tumor
[9]. Since then, ferrocene has been studied for potential
biological and medicinal applications [8, 10, 11]. Originally,
the oxidized species of ferrocene, ferrocenium (Cp2Fe+)w a s
reported to be responsible for the cytotoxic properties on
DNA mediated through its capacity to generate oxygen-free
radical species [12, 13]. Ferrocene has been recently reported
to have antitumor properties due to the metabolic formation
offerroceniumionswhichinducesoxidativedamagetoDNA
[14, 15]. As a result, many functionalized ferrocenes have
been prepared and tested in cancer cells [11].
We have initiated a project on functionalized ferrocene
chemistry, with pendant groups (functional groups, R) on
the Cp rings varying their polar and lipophilic characters,
see Scheme 1. The objective of this study is to understand
how the polar and lipophilic characters of the pendant
groups change the anticancer activity of the corresponding
ferrocenyl derivatives. We have investigated the synthesis,
structure, electrochemistry, and cytotoxic properties of ﬁve
ferrocenyl esters in HT-29 colon cancer and MCF-7 breast
cancer cell lines. The objective of this study is to report these
novel ﬁndings.2 Metal-Based Drugs
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Scheme 1: Structure of ferrocenyl ester complexes. R = CH3,
CH2CH3,C H 2CH2OH, and CH2CH=CH2.
2. Results andDiscussion
2.1. Synthesis and Structure. The syntheses of Fe(C5H4–
CO2CH3)2,F e ( C 5H4CO2CH2CH=CH2)2,a n dF e ( C 5H4–
CO2CH2CH2OH)2 have been reported previously [16, 17].
We applied the methodology developed by Busetto et al.
to synthesize Fe(C5H4CO2CH2CH3)2 and Fe(C5H4CO2–
CH2CH3)(C5H4CO2CH3)( m i x e df e r r o c e n e )[ 17]. Interest-
ingly, using this synthetic methodology, the reaction of
FeCl2 and one equivalent of NaC5H4CO2CH2CH3 and
NaC5H4CO2CH3, even at room temperature, allowed the
selective incorporation of two distinct functionalized Cp
ligands, aﬀording the mixed ferrocene complex in good
yield without the formation of Fe(C5H4CO2CH3)2 and
Fe(C5H4CO2CH2CH3)2.
The NMR, IR, and elemental analysis corroborate
the identities of the ferrocenyl ester complexes. The IR
spectral data showed ν(C=O) broadbands at 1708cm−1
(Fe(C5H4CO2CH2CH3)2 and 1712cm−1 (Fe(C5H4CO2–
CH2CH3)(C5H4CO2CH3) corresponding to the carbonyl
groups of the esters. In the 1H NMR spectrum, Fe(C5H4–
CO2CH2CH3)2 exhibits two set of resonances at 4.42 and
4.84ppm. These Cp protons exhibit coupling belonging
to an AA
 BB
  spin system. For the Fe(C5H4CO2CH2–
CH3)(C5H4CO2CH3), the 1H NMR spectrum shows two
sets of resonances at 4.42 and 4.85ppm corresponding to
the Cp protons of C5H4CO2CH2CH3 and C5H4CO2CH3
rings. While we might expect four sets of resonances in
the vinyl region corresponding to two diﬀerent substituted
Cp rings, the fact that we observed only two sets suggests
overlapping between these Cp proton signals. Particularly
interesting in the 13C NMR spectrum, at room temperature,
two sets of resonances for each carbon atom are observed
in a ratio of 1:1. This suggests that two possible conforma-
tional diastereoisomers, syn and anti, coexist in solution as
discussed below (Scheme 2)[ 18].
In solution, rapid ring oscillation about Cp–Fe–Cp axis
allows H2 and H5 (H
 
2 and H
 
5)a n dH 3 and H4 (H
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4) to become equivalents. This situation applies for both
substituted Cp rings. Since both Cp rings have ester groups,
overlapping of the H2/H5 and H
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5,H 3/H4 and H
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signals in the 1H NMR spectrum is expected. However,
the position of the ester groups yields to conformational
diastereoisomers,synandanti,whichdiﬀerintheorientation
of the carbonyl groups [18]. This condition applies when
the C(Cp)–C(CO) bond is slow in the NMR scale time.
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Scheme 2: Conformational diastereoisomers of Fe(C5H4CO2–
CH2CH3)(C5H4CO2CH3).
When the rotation is fast, having enough energy to overcome
the rotational barrier of the C(Cp)–C(CO) bond, such
stereolabile chirality disappears. In the 13C NMR spectrum,
the carbonyl orientation (syn and anti) makes signiﬁcantly
diﬀerent magnetic environment on the Cp carbons as well
as on the carbonyl groups such that two sets of resonances
corresponding to syn and anti conformers can be observed.
Variable temperature NMR studies, in toluene-d8, showed
t h a ta t8 0 ◦C in the 1H spectrum, the multiplet signal at
4.85ppm became a single line and the multiplet at 4.43ppm
broadened. These signals belong to the Cp rings. In the
13CN M Rs p e c t r u ma t8 0 ◦C, the carbon signals of one
conformer begin to increase in intensity at expense of the
other conformer, reaching a ratio of 1:2. This suggests that
conformational diastereoisomers, syn and anti,a tr o o m
temperature, have very similar stability but at high temper-
ature, one diastereoisomer (presumably) anti becomes more
populated.
In general, the present synthetic route developed by
Busetto et al. [17] for the ferrocenyl ester complexes
(Cp functionalization and formation of the corresponding
functionalized ferrocene) represents a convenient alternative
procedure for the functionalization of metallocenes and
has been used by our group to synthesize functionalized
titanocenes [19].
The solid-state structure of Fe(C5H4CO2CH3)2 was
investigated by single-crystal X-ray diﬀraction, see Figure 1.
Crystal data and structure reﬁnement are summarized
in the Supplementary Material available online at doi:
10.1155/2009/420784 (Cambridge Crystallographic Data
Centre and the deposition number is CCDC 705387).
Bonding parameters are included in Supplementary Table 1.
As shown by X-ray, this ferrocene is a sandwich complex
with the cyclopentadienyl ligands adopting an eclipsed
conformation and with the pendant groups not completely
opposite to each other. The average Fe–C(Cp) distances
for Fe(C5H4CO2CH3)2 are 2.049 and 2.048
 
˚ Aw h i c hi s
very similar to those reported for ferrocene, 2.045
 
˚ A[ 20].
The shortest Fe–C(Cp) bond distances are on C(5) and
C(7). The shorter bond distances could be attributed to the
inductive (electro-withdrawing) eﬀect of the ester groupsMetal-Based Drugs 3
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Figure 1: Solid-state structure of Fe(C5H4CO2CH3)2 drawn 50%
thermal ellipsoids. Average Fe-Cp bonds, Fe(C1–C5) 2.049(28) ˚ A
and Fe(C6–C10) bond 2.048 (11) ˚ A. Torsion angles for C(8)–C(7)–
C(11)–O(2) 6.9(4)
◦ and O(4)–C(13)–C(5)–C(1) 15.2(4)
◦.
on these carbon atoms. The ester groups are not coplanar
with the Cp ring, one of the OCH3 is bent toward the
iron atom (below the Cp plane) with a torsion angle of
15.2
◦ while the other is bent away from the iron atom
by 6.9
◦. The C(Cp)–C(CO) bonds (C(5)–C(13) and C(7)–
C(11)) are somewhat shorter than a typical C-C single
bond, 1.477(4) versus 1.54
 
˚ A (for a single bond), suggesting
these bonds have partial double bond character as a result
of conjugation with the Cp π system [21]. The later
might explain the high C(Cp)–C(CO) rotational barrier
encountered in the Fe(C5H4CO2CH2CH3)(C5H4CO2CH3)
complex.Inaddition,thetwoCO2Me groups are antito each
other.
While the solid structure of Fe(C5H4CO2CH3)2 has
been reported previously, our solid-state structure has a
fundamental diﬀerence to that published by Cetina et al.
[22]. That is, in the lattice, they determined a hydrogen
bonding network between the carbonyl group and the CH3
of the adjacent molecule. We could not determine such
hydrogen bonding network between the carbonyl group and
the CH3 of the adjacent molecule even though our data was
collected at lower temperature (173K versus 293K) and we
obtained better reﬁnement parameter (R (I > 2 sigma (I))
0.0397 versus 0.046).
2.2. Cyclic Voltammetry. Electrochemical characterization of
the subject complexes was performed by mean of cyclic
voltammetry (CV). It is well known that ferrocene easily
undergoes one electron oxidation to form ferrocenium
(Cp2Fe+) in a reversible manner. Thus, we investigated
the functionalized ferrocenes electrochemical behaviors and
compared to ferrocene in organic solvent. Table 1 presents
the CV results. As it can be seen in the cyclic voltammograms
(Figure 2), ferrocene and Fe(C5H4CO2CH3)2,a sw e l la sa l l
the remaining functionalized ferrocenes undergo a reversible
redox process with an ipa/ipc ratio close to one. All the
functionalized ferrocene demonstrated oxidation potentials,
Table 1: Redox potential of ferrocenyl esters in CH3CN 1M
CH3CN 1M [NBu
n
4]PF6 at a scan rate of 100mV/s, referenced
to ferrocene/ferrocenium redox couple. Ferrocene concentration of
2 × 10
−3 M. E1/2 is an average of the anodic and cathodic peaks
potentials.
Complex E1/2 (mV) ΔE( m V )
Fe(C5H4CO2CH3)2 454 75
Fe(CpCOOCH2CH3)2 448 74
Fe(CpCOOCH3)(CpCOOCH2CH3) 452 78
Fe(C5H4CO2CH2CH=CH2)2 453 85
Fe(C5H4CO2CH2CH2OH)2 456 89
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Figure 2: Cyclic voltammograms of complexes 2: Fe(CpCOOMe)2,
3: Fe(CpCOOEt)2, 4: Fe(CpCOOMe)(CpCOOEt), 5: Fe(CpCOO–
CH2CH=CH2)2, and 6: Fe(CpCOOCH2CH2OH)2 (2 × 10
−2 M) in
CH3CN (1 × 10
−3 MB u4NPF6) at room temperature. The working
electrodewasaplatinumdisk,referenceelectrodewasAg/AgCl,and
t h es c a nr a t ew a s1 0 0m v / s .
Epa, higher than ferrocene. This is the result of the electro-
withdrawing (inductive) eﬀect of the ester groups on the
Cp rings. Since ferrocene is known to undergo one-electron
redox process, it can be deduced that the subject complexes
also undergo one-electron redox change. Thus, this major
redox process on the functionalized ferrocenes is associated
to the ferrocene/ferrocenium couple.
2.3. Cytotoxic Studies—3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium Bromide (MTT): Colorimetric Assay for
Cytotoxicity Analysis on the Colon Cancer HT-29 and Breast
MCF-7 Cell Lines. The cytotoxicities of the ferrocenyl ester
complexes on the HT-29 colon cancer and MCF-7 breast
cancer cell lines were measured using a slightly modiﬁed
M T Ta s s a y[ 23, 24]. Ferrocene was initially evaluated at time
intervals of 72, 96, and 120 hours at concentrations that
rangedfrom10–1200μM,inHT-29,todetermineitsoptimal4 Metal-Based Drugs
Table 2:CytotoxicitiesofferrocenesstudiedonHT-29coloncancer
and MCF-7 breast cancer cell lines at 72 hours, as determined
by MTT assay. IC values are the average of four independent
measurements with their standard deviations ().
HT-29 MCF-7
Complex IC50 (μM) IC50 (μM)
FeCp2 360(30) 1500(100)
Fe(Cp–COOEt)2 370(10) 250(20)
Fe(Cp–COOMe)(Cp–COOEt) 500(20) 320(30)
Fe(Cp–COOMe)2 720(50) 520(20)
Fe(CpCOOCH2CH2OH)2 370(20) 340(30)
Fe(CpCOCH2CHCH2)2 180(10) 190(30)
Fe[Cp2]BF4 180(10) 150(05)
activity (Supplementary Figure 1S). Ferrocene displayed
comparable activity at all three time intervals, with an IC50
value of 3.6 × 10
−4 M. Since exposing the cells to ferrocene
at longer periods of time did not increase its cytotoxic
activity,allsubsequentexperimentswereperformedatadrug
exposure time of 72 hours. Ferrocene, ferrocenium, and the
functionalized complexes (–CO2R, R=Me, Et) were tested in
concentrations which ranged from 10–1200μM. In addition,
two control experiments were run 100% Medium and 5%
DMSO/95% Medium. Both control experiments behaved
identical demonstrating that 5% DMSO in the Medium
does not have any cytotoxic eﬀect on these cells. Table 2
summarizes the results of the cytotoxicity experiments and
Figure 3 depicts the cytotoxic curves from MTT assays
showing the eﬀect of the ferrocene complexes on the
viability of HT-29 colon cancer cell line. The IC50 value
represents the concentration of the ferrocene at which the
cell growth is inhibited by 50%. It can be noted that
bis(carboethoxycyclopentadienyl)ferrocene showed activity
comparable to ferrocene, with values of 370 and 360μM,
respectively but it has less cytotoxicity than ferroce-
nium (180μM). In contrast, (carboethoxycyclopentadienyl)-
(carbomethoxycyclopentadienyl)-ferrocene and the bis(car-
bomethoxycyclopentadienyl)-ferrocene exhibited less cyto-
toxic activity than ferrocene and ferrocenium. The car-
bomethoxy functionalization has been shown previously
to inactivate or lower the cytotoxic activity of resulting
titanocene complexes [19]. The present results clearly show
how the presence of the carbomethoxy substituent in the
cyclopentadienyl ring lowers the activity of ferrocene in
a stepwise manner, being the bis(carbomethoxy)ferrocene
less active than (carbomethoxy)(carboethoxy)ferrocene.
The carboethoxy functionalization does not improve the
activity of the ferrocene complexes as compared to
ferrocene.
Other ferrocenyl complexes, varying the lipophilic char-
acter of the carboalkoxy groups, were also evaluated for
cytotoxic activity against HT-29 cells. Ferrocene complexes
with either terminal alcohol or allyl groups were tested
in concentrations that ranged from 13 to 1300μMa ta
72-hour time interval. IC50 values for these complexes
are also summarized in Table 2,a n dFigure 4 shows the
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Figure3:Dose-responsecurvesforfunctionalizedcyclopentadienyl
ferrocenes against HT-29 cells at 72 hours drug exposure. Leg-
end: ferrocene-diamonds, bis(carbomethoxy)-squares, bis(carboet-
hoxy)-triangles, and (carbomethoxy)(carboethoxy)-circles.
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Figure 4: Dose-response curves for functionalized ferrocene com-
plexes on HT-29 colon adenocarcinoma cells at 72 hours. Complex
with terminal alcohol (diamonds), complex with terminal allyl
(squares), ferrocene (triangles), and ferrocenium ion (circles).
cytotoxic curves for these complexes along with ferrocene
and ferrocenium for comparison. The ferrocene alcohol
complex shows an IC50 value of 370μMw h i c hi sc o m -
parable to ferrocene, while (allyl) complex shows higher
cytotoxic activity than ferrocene and equal to the ferroce-
nium at the time interval studied, with an IC50 value of
180μM.
The initial work performed by Kopf-Maier et al. demon-
strated that ferrocenium possesses in vivo anticancer activity
in breast cancer [9]. Based on this precedent, we investigated
our functionalized ferrocenes in MCF-7 breast cancer cell
line. Surprisingly, ferrocene showed to be less cytotoxic in
breast cancer than in colon cancer. With regard to the func-
tionalized ferrocenes and similar to the results on HT-29 cell
line, a pattern in the cytotoxicity as we change the functional
group (pendant group) is evident. First, in the ferrocenyl
with carboalkoxy groups, the incorporation of methyl ester
(–CO2CH3) groups on the Cp rings decreases the cytotoxic
activity of the resulting complexes. Second, see Figure 5, the
increase in the lipophilic character on the carboalkoxy sub-
stituents such as in Fe(C5H4CO2CH2CH=CH2)2, where the
ethylgroupissubstitutedbyanoleﬁn,increasesthecytotoxic
activity. Such behavior has been reported previously by two-
independent research groups, as described below [12, 25].Metal-Based Drugs 5
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Figure 5: Dose-response curves for functionalized ferrocene
complexes on MCF-7 breast cancer cells at 72 hours. Ferro-
cene(diamonds), ferrocenium(squares), bis(carboethoxy)(trian-
gles), and terminal allyl (circles).
A wide variety of ferrocenyl derivatives have been
synthesized by several research groups aimed to improve
their anticancer activity as well as to understand the
structure-activity relationship. Very active ferrocenyl deriva-
tives have been synthesized containing estrogen receptor
modulators as pendant groups [26]. Among them, 1,1 -bis-
(4 -hydroxyphenyl)-2-ferrocenyl-but-1-ene showed strong
antiproliferativeactivityinbothhormone-dependent(MCF-
7) and hormone-independent (MDA-MDA231) breast can-
cer cells with IC50 = 0.7a n d0 . 6 μM, respectively [26].
On the other hand, ferrocenyl carbohydrate conjugates
prepared by Orvig et al. showed IC50 values between 87–
468μM on HTB-129 human breast cancer cell line [27].
Our ferrocenyl esters showed IC50 values similar to those of
the ferrocenyl carbohydrates [27] and ferrocenium deriva-
tives tested on MCF-7 cell line: ferroceniumcarboxylic acid
tetraﬂuoroborate (IC50 = 340μM), decamethylferrocene
tetraﬂuoroborate (IC50 = 37μM), 1,1 -dimethylferrocenium
tetraﬂuoroborate(IC50 = 320μM),andferroceniumboronic
acid tetraﬂuoroborate IC50 = 317μM) [12]. It should be
clearly noticed that, as reported previously, the increase in
the lipophilic character on the ferrocene or ferrocenium
complex increases the cytotoxic activity [12, 25].
For colon cancer, the cytotoxic data is more limited
for a more meaningful comparison and assessment. On a
recent review on the medicinal properties of ferrocenes, it
was described a series of ferrocene conjugates (functional-
ized) anchored to polyaspartimides (water soluble carrier
polymers) and evaluated on Colo and Hela colon cancer
cell lines [11, 28]. The IC50 values determined are in
the 10
−4–10
−5 M range, analogous to some of our most
active species. From these studies, Neuse et al. found that
increasing the hydrophilicity of the polyaspartimide side
chains does not necessarily improve the cytotoxicity of the
resulting ferrocenes, similar to our ﬁndings [28]. On the
other hand, opposite to our ﬁndings, Kenny et al. studied the
antiproliferative eﬀect of a series of N-(ferrocenyl)benzoyl
dipeptide esters on H1229 lung cancer cells and found that
increasing the alkyl chain length of the amino acid lower the
cytotoxic activity [29]. However, since the data come from
diﬀerent cancer cell lines, the comparison of the IC50 values
b e c o m e sl e s sa c c u r a t e .
Finally, an important conclusion derived from this study
is that minor changes in the pendant group on the Cp
ring may have notable impact in the cytotoxic activity of
the resulting ferrocenes. This is in good agreement with
previous reports [12, 25]. Increasing the lipophilic character
of the ferrocenyl esters apparently improves their biological
activity, as a result of better transport of these species
into the target place inside the cell [12, 13, 25]. This
increased lipophilic character on the ferrocenes increases
the cell uptake (improving cell membrane permeability of
the ferrocene), and more ferrocene molecules could become
available inside the cell to express their activity. It has been
proposed by Lander et al. that not only ferrocenium cation
but also ferrocene is able to express oxidative stress [15].
F e r r o c e n ei sa b l et og e n e r a t eH 2O2 by autooxidation, form-
ingferroceniumions.Theimmune-stimulatorypropertiesof
ferrocene are postulated to be mediated by redox-sensitive
signaling proteins [15].
3. Experimental
3.1. General Procedure. All reactions were performed under
an atmosphere of dry nitrogen using Schlenk glassware
or a glovebox, unless otherwise stated. Reaction vessels
were ﬂame dried under a stream of nitrogen, and anhy-
drous solvents were transferred by oven-dried syringes or
cannula. Tetrahydrofuran was dried and deoxygenated by
distillation over K-benzophenone under nitrogen. Infrared
spectra were recorded on a Brucker Vector-22 spectrometer
with the samples as compressed KBr discs. The NMR
s p e c t r aw e r eo b t a i n e do na5 0 0M H zB r u k e rs p e c t r o m e t e r .
Elemental analyses were obtained from Atlantic Microlab,
Inc., Ga, USA. Electrochemical characterization was car-
ried out on a BAS CV050W voltammetric analyzer of
Bioanalytical Systems, Inc. with a three-stand electrode
cell. Cyclic voltammetric experiments were performed in
deoxygenated CH3CN solution of ferrocene complexes with
1M of [NBun
4PF6 as supporting electrolyte and ferrocene
complex concentration of 2 × 10
−3M. The three electrodes
used were platinum disk as the working electrode, Ag/AgCl
as a reference electrode, and Pt wire as an auxiliary electrode.
The working electrode was polished with 0.05μm alumina
slurry for 1–2 minutes, and then rinsed with double-distilled
and deionized water. This cleaning process is done before
each CV experiment and a sweep between 0 and 2000 mV is
performed on the electrolyte solution to detect any possible
deposition of ferrocene on the electrode surface.
Dimethyl carbonate, diethyl carbonate, diallyl carbon-
ate, ethylene carbonate, diethyl ether (anhydrous ≥99.7%),
anhydrous FeCl2,[ C p 2Fe]BF4, and CDCl3 were purchased
from Sigma-Aldrich. NaCp was prepared in situ by reacting
freshly distilled cyclopentadiene and NaH in THF. Silica
gel was heated at about 200◦C while a slow stream of dry
nitrogen was passed through it.
The syntheses of sodium 1-carbomethoxycyclopentadi-
enide (NaCpCOOCH3) and sodium 1-carboethoxycyclo-
pentadienide (NaCpCOOCH2CH3)h a v eb e e nr e p o r t e dp r e -
v i o u s l yb yo u rg r o u p[ 18].6 Metal-Based Drugs
The colon cancer cell line HT-29 and the breast adeno-
carcinoma cell line MCF7 were purchased from American
Type Culture Collection, Va, USA, and were at 37◦Ca n d
95% Air/5%CO2. Growth medium for HT-29 was McCoy’s
5A complete medium supplemented with 10% (v/v) fetal
bovine serum and 1% (v/v) antibiotic/antimycotic. Growth
medium for MCF7 was Eagle’s Minimum Essential Media
supplemented with 10% (v/v) fetal bovine serum, 1%
(v/v) antibiotic/antimycotic, nonessential amino acids, and
0.01mg/mL bovine insulin. MTT and Triton X-100 used
for the cytotoxic assay were obtained from Sigma. All MTT
manipulations were performed in a dark room.
3.2. Synthesis
3.2.1. Synthesis of 1,1 -bis(carbomethoxy)-ferrocene (Fe (Cp–
COOCH3)2). To a solution of NaCpCOOCH3 (0.47g,
3.1mmol) in THF 20mL, was added solid FeCl2 (0.2g,
1.5mmol). The solution was stirred for 24 hours at room
temperature. The solvent was removed under vacuum, and
CH2Cl2was added; the red suspension was ﬁrst ﬁltered
on a Celite pad and then chromatographed on silica gel
eluting with Et2O to give 0.45g (95%) of orange viscous
oil. The product was redissolved in chloroform/hexane (1:9)
at −20◦C and orange solid could be obtained.1HNMR
(500MHz,CDCl3):δ(ppm)3.85(s,6H;–OCH3),4.43[t,4H,
3J(H, H) = 1.5Hz, AA
 BB
 ; Cp], 4.85[t, 4H, 3J (H, H) =
1.5Hz; AA
 BB
 ; Cp].13CNMR(125MHz, CDCl3): δ(ppm)
51.71(–OCH3), 71.61(CH; Cp), 72.62(CH; Cp), 72.89(ipso-
C; Cp), 170.82(C=O). IR (KBr, cm−1): 2957, 1703, 1470,
1288, 1197, 1147, 965, 780. Anal. Calcd for C14H14O4Fe: C,
55.67; H, 4.64. Found: C, 56.01; H, 4.74.
3.2.2. Synthesis of 1,1 -bis(carboethoxy)-ferrocene (Fe(Cp–
COOCH2CH3)2. To a solution of NaCpCOOCH2CH3
(0.50g, 3.16mmol) in THF 20mL, was added solid FeCl2
(0.2g, 1.58mmol). The solution was stirred for 24 hours at
room temperature. The solvent was removed under vacuum,
and CH2Cl2 was added; the red suspension was ﬁrst ﬁltered
on a Celite pad and then chromatographed on silica gel
eluting with Et2O to give 0.48g (92%) of orange viscous
oil. The product was resolved in chloroform/hexane (1:12)
at −20◦C and orange solid could be obtained. 1HNMR
(500MHz, CDCl3): δ(ppm) 1.38(t, 6H, 3J (H, H) = 7.0Hz;
–OCH2CH3), 4.31(q, 4H, 3J (H, H) = 7.0Hz; –OCH2CH3),
4.42[t, 4H, 3J (H, H) = 1.5Hz, AA
 BB
 ; Cp], 4.84[t, 4H, 3J
(H, H) = 1.5Hz; AA
 BB
 ; Cp].13CNMR(125MHz, CDCl3):
δ(ppm) 14.53(–OCH2CH3), 60.43(–OCH2CH3), 71.53(CH;
Cp), 72.71(CH; Cp), 73.16(ipso-C; Cp), 170.43(C=O). IR
(KBr, cm−1): 2985, 2936, 1708, 1479, 1457, 1379, 1282, 1144,
1030, 1017, 774. Anal. Calcd for C16H18O4Fe: C, 58.22; H,
5.46. Found: C, 58.19; H, 5.48.
3.2.3. Synthesis of 1-(carbomethoxy)-1 -(carboethoxy)-ferro-
cene (Fe(CpCOOCH3) (CpCOOCH2CH3). To a solution
of NaCpCOOCH3 (0.23g, 1.58mmol) and NaCpCOO–
CH2CH3 (0.25g, 1.58mmol) in THF 20mL, was added solid
FeCl2 (0.2g, 1.58mmol). The solution was stirred for 24
hours at room temperature. The solvent was removed under
vacuum, and CH2Cl2 was added; the red suspension was
ﬁrst ﬁltered on a Celite pad and then chromatographed
on silica gel eluting with Et2O to give 0.46g (92%) of
orange viscous oil. The product was dissolved in chloro-
form/hexane (1:10) at −20◦C and orange solid could be
obtained.1HNMR (500MHz, CDCl3): δ(ppm) 1.39(t, 3H, 3J
(H, H) = 7.0Hz; –OCH2CH3), 3.85, 3.86
∗(s, 3H; –OCH3),
4.32(q, 2H, 3J (H, H) = 7.0Hz; –OCH2CH3), 4.43[m, 4H;
Cp], 4.85[m, 4H; Cp].13CNMR(125MHz, CDCl3): δ(ppm)
14.52, 14.55
∗(–OCH2CH3), 51.76(–OCH3), 60.46, 60.48
∗
(–OCH2CH3), 71.57, 71.61
∗(CH; Cp), 72.73, 72.77
∗(CH;
Cp), 72.86, 73.21
∗(ipso-C; Cp), 170.43, 170.49
∗(C=O),
170.87, 170.95
∗(C=O). IR (KBr, cm−1): 2995, 2950,
1712, 1472, 1284,1143, 1030, 774, 514. Anal. Calcd for
C15H16O4Fe: C, 57.00; H, 5.07. Found: C, 57.19; H, 5.08.
T h et w oc o m p l e x e s[ F e ( C 5H4CO2CH2CH=CH2)2]a n d
[Fe{C5H4CO2(CH2)2OH}2] were prepared as described by
Busetto et al. from sodium cyclopentadenide and diallyl
carbonate or solid ethylene carbonate [17].
3.3. Cytotoxic Assay. Biological activity was determined
using the MTT assay originally described by Mossman
[19a] but using 10% Triton in isopropanol as a solvent for
the MTT formazan crystals [19b]. HT-29 and MCF7 cells
were maintained at 37◦C and 95% Air/5%CO2 in McCoy’s
5A (ATCC) complete medium, which had been supple-
mented with 10% (v/v) fetal bovine serum (ATCC) and
1% (v/v) antibiotic/antimycotic (Sigma). Asynchronously,
growing cells were seeded at 1.5 × 104 cells per well in 96-
well plates containing 100μLo fc o m p l e t eg r o w t hm e d i u m ,
and allowed to recover overnight. Various concentrations of
the complexes (10–1300μM) dissolved in 5% DMSO/95%
Medium were added to the wells (eight wells per concentra-
tion, experiments performed in quadruplicate plates). The
complexes solutions were prepared ﬁrst by dissolving the
corresponding ferrocene in DMSO and then Medium was
added to a ﬁnal composition of 5% DMSO/95% Medium. In
addition to the cells treated with the ferrocenes, two controls
experiments were run one without any addition of solvent
mixture (5% DMSO/95% Medium) and one adding 5%
DMSO/95% Medium to the cells. Both control experiments
behavedidentical,showingthat5%ofDMSOintheMedium
did not render toxic to these types of cells. The cells were
incubated for an additional 70 hours. After this time, MTT
dissolved in complete growth medium was added to each
well to a ﬁnal concentration of 1.0mg/mL and incubated
for two additional hours. After this period of time, all MTTs
containing medium were removed, cells were washed with
cold PBS and dissolved with 200μL of a 10% (v/v) Triton
X-100 solution in isopropanol. After complete dissolution
of the formazan crystals, well absorbances were recorded
in triplicates on a 340 ATTC Microplate Reader (SLT Lab
Instruments) at 570nm with background subtraction at
630nm. Concentrations of compounds required to inhibit
cell proliferation by 50% (IC50) were calculated by ﬁtting
data to a four-parameter logistic plot by means of SigmaPlot
software from SPSS, Ill, USA.Metal-Based Drugs 7
3.4. X-Ray Crystallographic Analysis. A light orange needle
crystal with 0.15 × 0.04 × 0.01mm in size was mounted
on a cryoloop with Paratone oil. Data was collected in
a nitrogen gas stream at −173◦Co naB r u k e rS m a r t
system. Data collection was 99.6% complete to 25
◦ in θ.
The data was integrated using the Bruker SAINT software
program. The structure was solved by direct methods and
all nonhydrogen atoms were reﬁned anisotropically by full-
matrix least-squares (SHELXL-97). The crystal structure
has been deposited at the Cambridge Crystallographic Data
Centre and the deposition number is CCDC 705387.
Acknowledgments
E. Mel´ endez acknowledges the NIH-MBRS SCORE Pro-
grams at both the University of Puerto Rico, Mayag¨ uez,
USA and the Ponce School of Medicine for ﬁnancial
support via NIH-MBRS-SCORE Program Grant no. S06
GM008239-23 and the PSM-Moﬃtt Cancer Center Partner-
ship 1U56CA126379-01. In addition, E. Mel´ endez thanks
NSF-MRI Program for providing funds for the purchasing of
the 500MHz NMR instrument, School of Crystallography,
the University of California, San Diego, Calif, USA, and
Professor Arnold Rheingold and Dr. Antonio Dipasquale
for the X-ray facility and to the Sloan Foundation for
ﬁnancial support in the form of a graduate fellowship to R.
Hern´ andez.
References
[1] T. J. Kealy and P. L. Pauson, “A new type of organo-iron
compound,” Nature, vol. 168, no. 4285, pp. 1039–1040, 1951.
[2] S. A. Miller, J. A. Tebboth, and J. F. Tremaine,
“Dicyclopentadienyliron,” Journal of the Chemical Society,
pp. 632–635, 1952.
[ 3 ] A .T o gn ia n dT .H a y a s h i ,E d s . ,Ferrocenes: Homogeneous Catal-
ysis/Organic Synthesis/Materials Science, Wiley-VCH, Wein-
heim, Germany, 1995.
[4] R. G´ omez Array´ as, J. Adrio, and J. C. Carretero, “Recent appli-
cations of chiral ferrocene ligands in asymmetric catalysis,”
AngewandteChemie—InternationalEdition,vol.45,no.46,pp.
7674–7715, 2006.
[ 5 ] A .T o g n ia n dR .L .H a l t e r m a n ,E d s . ,Metallocenes, Wiley-VCH,
Weinheim, Germany, 1998.
[6] R. C. J. Atkinson, V. C. Gibson, and N. J. Long, “The syn-
theses and catalytic applications of unsymmetrical ferrocene
ligands,” Chemical Society Reviews, vol. 33, no. 5, pp. 313–328,
2004.
[7] H. K¨ opf and P. K¨ opf-Maier, “Titanocene dichloride—the
ﬁrst metallocene with cancerostatic activity,” Angewandte
Chemie—International Edition in English,v o l .1 8 ,n o .6 ,p p .
477–478, 1979.
[8] G. Jaouen, Ed., Bioorganometallics, Wiley-VCH, Weinheim,
Germany, 2006.
[9] P. K¨ opf-Maier, H. K¨ opf, and E. W. Neuse, “Ferricenium
complexes: a new type of water-soluble antitumor agent,”
Journal of Cancer Research and Clinical Oncology, vol. 108, no.
3, pp. 336–340, 1984.
[10] D. R. van Staveren and N. Metzler-Nolte, “Bioorganometallic
chemistryofferrocene,”ChemicalReviews,vol.104,no.12,pp.
5931–5985, 2004.
[ 1 1 ] M .F .R .F o u d a ,M .M .A b d - E I z a h e r ,R .A .A b d e l s a m a i a ,a n dA .
A. Labib, “On the medicinal chemistry of ferrocene,” Applied
Organometallic Chemistry, vol. 21, no. 8, pp. 613–625, 2007.
[12] G. Tabb` ı, C. Cassino, G. Cavigiolio, et al., “Water stability
and cytotoxic activity relationship of a series of ferrocenium
derivatives. ESR insights on the radical production during the
degradation process,” Journal of Medicinal Chemistry, vol. 45,
no. 26, pp. 5786–5796, 2002.
[13] D. Osella, H. Mahboobi, D. Colangelo, G. Cavigiolio, A.
Vessi` eres, and G. Jaouen, “FACS analysis of oxidative stress
induced on tumour cells by SERMs,” Inorganica Chimica Acta,
vol. 358, no. 6, pp. 1993–1998, 2005.
[14] H. Tamura and M. Miwa, “DNA cleaving activity and
cytotoxic activity of ferricenium cations,” Chemistry Letters,
vol. 26, no. 11, pp. 1177–1178, 1997.
[15] R. Kovjazin, T. Eldar, M. Patya, A. Vanichkin, H. M. Lander,
and A. Novogrodsky, “Ferrocene-induced lymphocyte activa-
tion and anti-tumor activity is mediated by redox-sensitive
signaling,” The FASEB Journal, vol. 17, no. 3, pp. 467–469,
2003.
[16] T. W. Spradau and J. A. Katzenellenbogen, “Preparation
of cyclopentadienyltricarbonylrhenium complexes using a
double ligand-transfer reaction,” Organometallics, vol. 17, no.
10, pp. 2009–2017, 1998.
[17] L. Busetto, M. C. Cassani, V. G. Albano, and P. Sabatino,
“Coordination chemistry of ester-functionalized Cp ligands.
The atom-economy synthesis of Na[C5H4CO2(CH2)2OH],
solid state structures of [Rh{C5H4CO2(CH2)2OH}(CO)2]
and [Rh2{μ-(C5H4CO2CH2)2}(NBD)2],” Organometallics,
vol. 21, no. 9, pp. 1849–1855, 2002.
[18] B. F. Bonini, M. Fochi, L. Lunazzi, and A. Mazzanti,
“Conformational studies by dynamic NMR. 72. Stereolabile
enantiomers of acyl and thioacyl ferrocenes,” Journal of
Organic Chemistry, vol. 65, no. 8, pp. 2596–2598, 2000.
[19] L. M. Gao, R. Hern´ andez, J. Matta, and E. Mel´ endez, “Synthe-
sis, Ti(IV) intake by apotransferrin and cytotoxic properties
of functionalized titanocene dichlorides,” Journal of Biological
Inorganic Chemistry, vol. 12, no. 7, pp. 959–967, 2007.
[20] J. D. Dunitz, L. E. Orgel, and A. Rich, “The crystal structure of
ferrocene,” Acta Crystallographica, vol. 9, part 4, pp. 373–375,
1956.
[21] L. Pauling, The Nature of the Chemical Bond, Cornell Univer-
sity Press, Ithaca, NY, USA, 3rd edition, 1960.
[22] M. Cetina, M. Juki´ c, V. Rapi´ c, and A. Golobiˇ c, “Fer-
rocene compounds. XXXVIII. Di-methyl ferrocene-1,1 -
dicarboxylate,” Acta Crystallographica Section C,v o l .5 9 ,n o .6 ,
pp. m212–m214, 2003.
[23] T. Mosmann, “Rapid colorimetric assay for cellular growth
and survival: application to proliferation and cytotoxicity
assays,” Journal of Immunological Methods,v o l .6 5 ,n o .1 - 2 ,p p .
55–63, 1983.
[24] F. Denizot and R. Lang, “Rapid colorimetric assay for cell
growth and survival: modiﬁcations to the tetrazolium dye
procedure giving improved sensitivity and reliability,” Journal
of Immunological Methods, vol. 89, no. 2, pp. 271–277, 1986.
[25] P.James,J.Neud¨ orﬂ,M.Eissmann,P.Jesse,A.Prokop,andH.-
G. Schmalz, “Enantioselective synthesis of ferrocenyl nucle-
oside analogues with apoptosis-inducing activity,” Organic
Letters, vol. 8, no. 13, pp. 2763–2766, 2006.
[26] A. Vessi` eres, S. Top, P. Pigeon, et al., “Modiﬁcation of the
estrogenic properties of diphenols by the incorporation of
ferrocene. Generation of antiproliferative eﬀects in vitro,”
Journal of Medicinal Chemistry, vol. 48, no. 12, pp. 3937–3940,
2005.8 Metal-Based Drugs
[ 2 7 ]C .L .F e r r e i r a ,C .B .E w a r t ,C .A .B a r t a ,e ta l . ,“ S y n t h e s i s ,
structure, and biological activity of ferrocenyl carbohydrate
conjugates,” Inorganic Chemistry, vol. 45, no. 20, pp. 8414–
8422, 2006.
[ 2 8 ]G .C a l d w e l l ,M .G .M e i r i m ,E .W .N e u s e ,a n dC .E .J .
van Rensburg, “Antineoplastic activity of polyaspartamide-
ferrocene conjugates,” Applied Organometallic Chemistry, vol.
12, no. 12, pp. 793–799, 1998.
[29] A. J. Corey, N. O’Donovan, ´ A .M o o n e y ,D .O ’ S u l l i v a n ,D .
K. Rai, and P. T. M. Kenny, “Synthesis, structural char-
acterization, in vitro anti-proliferative eﬀect and cell cycle
analysis of N-(ferrocenyl)benzoyl dipeptide esters,” Journal of
Organometallic Chemistry. In press.